Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don’t Expect More Gains.

Text dimension Moderna’s vaccine has confirmed the worth of its mRNA know-how. Munir Uz zaman/AFP through Getty Images Biotech firm

Read more